Strata Critical Medical, Inc. cash flow to debt ratio of -1.48K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Strata Critical Medical, Inc.'s free cash flow has decreased 68.74% from $-35.51M last year to $-59.92M, signaling decreasing performance

Strata Critical Medical, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Strata Critical Medical, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.02 today, signaling strengthened financials

Strata Critical Medical, Inc. has negative EBITDA, making leverage ratio unreliable

Strata Critical Medical, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Strata Critical Medical, Inc.'s profit margin has increased (-268.32%) in the last year from -10.98% to 18.48%, signaling increasing performance

Strata Critical Medical, Inc.'s short-term assets of $126.19M exceed its short-term liabilities of $19.79M

Strata Critical Medical, Inc.'s return on assets of 14.34% is higher than the 5.00% threshold, indicating efficient asset utilization

Strata Critical Medical, Inc.'s return on equity of 17.55%, is higher than 15.00%, indicating good performance

Strata Critical Medical, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Strata Critical Medical, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Strata Critical Medical, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Strata Critical Medical, Inc. has negative free cash flow, indicating cash burn

Strata Critical Medical, Inc.'s yearly earnings has increased -251.42% since last year from $-27.31M to $41.35M, signaling increasing performance

Strata Critical Medical, Inc.'s yearly revenue has decreased -20.73% since last year from $248.69M to $197.14M, signaling decreasing performance

ROIC -6.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Strata Critical Medical, Inc.'s 3-year revenue CAGR of 10.50% is positive, indicating growing revenue over the past 3 years

Strata Critical Medical, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Strata Critical Medical, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Strata Critical Medical, Inc. has insufficient data to evaluate this check.

Strata Critical Medical, Inc. has an earnings yield of 10.43%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Strata Critical Medical, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Strata Critical Medical, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Strata Critical Medical, Inc. is overvalued relative to its fair value price of -14.00 based on Earnings Fair Value model

Strata Critical Medical, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.

Strata Critical Medical, Inc. has a price-to-book ratio of 1.58x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Strata Critical Medical, Inc. has a price-to-sales ratio of 1.77x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue